A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 563,500 shares of FULC stock, worth $1.96 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
563,500
Previous 420,200 34.1%
Holding current value
$1.96 Million
Previous $3.97 Million 11.93%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.98 - $9.31 $856,934 - $1.33 Million
143,300 Added 34.1%
563,500 $3.49 Million
Q1 2024

May 15, 2024

SELL
$6.7 - $12.0 $509,200 - $912,000
-76,000 Reduced 15.32%
420,200 $3.97 Million
Q4 2023

Feb 14, 2024

SELL
$3.18 - $6.86 $82,044 - $176,988
-25,800 Reduced 4.94%
496,200 $3.35 Million
Q3 2023

Nov 14, 2023

SELL
$3.25 - $6.08 $238,225 - $445,664
-73,300 Reduced 12.31%
522,000 $2.32 Million
Q2 2023

Aug 14, 2023

BUY
$2.26 - $3.8 $751,901 - $1.26 Million
332,700 Added 126.69%
595,300 $1.96 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $562,038 - $2.78 Million
198,600 Added 310.31%
262,600 $748,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $68,637 - $114,395
13,700 Added 27.24%
64,000 $465,000
Q3 2022

Nov 14, 2022

SELL
$4.92 - $9.1 $300,120 - $555,100
-61,000 Reduced 54.81%
50,300 $407,000
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $108,360 - $619,200
25,800 Added 30.18%
111,300 $545,000
Q1 2022

May 16, 2022

SELL
$9.96 - $23.65 $2.92 Million - $6.94 Million
-293,600 Reduced 77.45%
85,500 $2.02 Million
Q4 2021

Feb 14, 2022

BUY
$14.0 - $28.44 $3.32 Million - $6.74 Million
236,900 Added 166.6%
379,100 $6.71 Million
Q3 2021

Nov 15, 2021

BUY
$7.28 - $30.97 $1.04 Million - $4.4 Million
142,200 New
142,200 $4.01 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $181M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.